Anand Rotte

Codex Biosolutions (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Madhuri Bhandaru

University of British Columbia

Florian Läng

Hangzhou Wanxiang Polytechnic

Venkanna Pasham

University of Tübingen

Jeyakumar Subbaroyan

Nyxoah (Belgium)

Wenting Yang

Tea Research Institute

David Caraway

Nevro (United States)

Christopher R. Heery

Bavarian Nordic (United States)

Bradford E. Gliner

Nevro (United States)

Kasra Amirdelfan

Kaiser Permanente Walnut Creek Medical Center

Matthew J. Frigault

Massachusetts General Hospital

Cooperative Institutions

New York Academy of Sciences

John Wiley & Sons (United States)

Hudson Institute

University of Tübingen

Albert Einstein College of Medicine

John Wiley & Sons (Germany)

Moss Landing Marine Laboratories

Liechtenstein Institute

Montefiore Medical Center

Middle East Institute

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Amelioration of lower limb pain and foot drop with 10 kHz spinal cord stimulation: A case series

Journal of International Medical Research (2021)

Honghui Feng Patrick Doherty Anand Rotte Christopher Bovinet

There are limited treatment options for patients with foot drop and associated lower back and/or leg pain. We present a case series of three patients who received permanent implantation of 10 kHz spinal cord stimulation (10 kHz SCS) devices. Following treatment, all patients reported sustained improvements in lower back and leg pain, foot mechanics and function which resulted in increased mobility and cessation of opioid use for pain management. Patients were followed up for approximately four years. Treatment with 10 kHz SCS may be a promising alternative to other interventional procedures commonly used for these patients.

Foot drop

Foot (prosody)

Spinal cord stimulator

10.1177/03000605211005954

Cite

Citations (3)

Influence of Dexamethasone on Na+/H+ Exchanger Activity in Dendritic Cells

Cellular Physiology and Biochemistry (2011)

Anand Rotte Venkanna Pasham Melanie Eichenmüller Wenting Yang Madhuri Bhandaru

Glucocorticoids regulate the function of dendritic cells (DCs), antigen-presenting cells linking innate and adaptive immunity. Glucocorticoids influence the function of other cell types by modulating the activity of the Na+/H+exchanger (NHE), a carrier involved in the regulation of cytosolic pH and cell volume. The present study explored whether dexamethasone influences Na+/H+ exchanger activity in DCs. The DCs were isolated from mouse bone marrow, cell volume was estimated from forward scatter in FACS analysis, cytosolic pH (pHi) utilizing BCECF fluorescence and Na+/H+ exchanger activity from the Na+ dependent realkalinization after an ammonium pulse. Treatment with the glucocorticoid dexamethasone (100 nM; 1, 4, 16 and 24h) significantly decreased pHi (≧4 h) and gradually increased Na+/H+ exchanger activity (=16 h). The stimulation of Na+/H+ exchanger activity by dexamethasone was virtually abrogated by glucocorticoid receptor blocker mefiprestone (1 µM) and NHE3 inhibitor dimethyl amiloride (5 µM), but not prevented by NHE1 inhibitor cariporide (10 µM). Dexamethasone treatment significantly increased SGK1 mRNA levels. Stimulation of Na+/H+ exchanger activity by dexamethasone was blunted in DCs lacking SGK1. Dexamethasone treatment did not significantly alter ROS formation but significantly decreased the forward scatter. Exposure of DCs to lipopolysacharide (LPS, 1 µg/ml) led to a transient increase followed by a decline of Na+/H+ exchanger activity and to enhanced forward scatter as well as ROS formation, all effects significantly blunted in the presence of dexamethasone (100 nM). In conclusion, glucocorticoid treatment decreased pHi and cell volume, effects paralleled by upregulation of Na+/H+ exchanger activity in DCs. Moreover, glucocorticoids blunted the stimulation of Na+/H+ exchanger activity, cell swelling and ROS formation following LPS treatment.

10.1159/000331746

Cite

Citations (28)

Upregulation of Intestinal NHE3 Following Saline Ingestion

Kidney & Blood Pressure Research (2013)

Venkanna Pasham Anand Rotte Shuchen Gu Wenting Yang Madhuri Bhandaru

Background: Little is known about the effect of salt content of ingested fluid on intestinal transport processes. Osmosensitive genes include the serum- and glucocorticoid-inducible kinase SGK1, which is up-regulated by hyperosmolarity and cell shrinkage. SGK1 is in turn a powerful stimulator of the intestinal Na+/H+ exchanger NHE3. The present study was thus performed to elucidate, whether the NaCl content of beverages influences NHE3 activity. Methods: Mice were offered access to either plain water or isotonic saline ad libitum. NHE3 transcript levels and protein abundance in intestinal tissue were determined by confocal immunofluorescent microscopy, RT-PCR and western blotting, cytosolic pH (pHi) in intestinal cells from 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF) fluorescence and Na+/H+ exchanger activity from the Na+ dependent realkalinization following an ammonium pulse. Results: Saline drinking significantly enhanced fluid intake and increased NHE3 transcript levels, NHE3 protein and Na+/H+ exchanger activity. Conclusions: Salt content of ingested fluid has a profound effect on intestinal Na+/H+ exchanger expression and activity.

Sodium–hydrogen antiporter

10.1159/000343401

Cite

Citations (14)

Stimulation of electrogenic intestinal dipeptide transport by the glucocorticoid dexamethasone

Pflügers Archiv - European Journal of Physiology (2009)

Rexhep Rexhepaj Anand Rotte Daniela S. Kempe Mentor Sopjani Michael Föller

SGK1

10.1007/s00424-009-0701-z

Cite

Citations (18)

Regulation of Na+/H+ exchanger in dendritic cells by Akt2

Pflügers Archiv - European Journal of Physiology (2011)

Madhuri Bhandaru Wenting Yang Anand Rotte Venkanna Pasham Florian Läng

Sodium–hydrogen antiporter

AKT2

10.1007/s00424-011-1015-5

Cite

Citations (9)

Mechanisms of Immune Evasion by Cancer

Springer eBooks (2016)

Anand Rotte Madhuri Bhandaru

Immunosurveillance

Immunoediting

10.1007/978-3-319-48066-4_8

Cite

Citations (5)

MMP2 expression is a prognostic marker for primary melanoma patients

Cellular Oncology (2012)

Anand Rotte Magdalena Martinka Gang Li

MMP2

Tissue microarray

Tumor progression

10.1007/s13402-012-0080-x

Cite

Citations (75)

Nobel committee honors tumor immunologists

Journal of Experimental & Clinical Cancer Research (2018)

Anand Rotte Gabriella D’Orazi Madhuri Bhandaru

This commentary wishes to highlight the 2018 Nobel Prize in Medicine awarded to two cancer immunotherapy scientists, Prof James Allison and Prof Tasuku Honjo, for their discovery on unleashing the body's immune system to attack cancer. Their studies have led to the development of an entire class of drugs that hopefully will bring lasting remissions to many patients who had run out of options.

10.1186/s13046-018-0937-6

Cite

Citations (48)

Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective

Expert Review of Clinical Pharmacology (2023)

Pratap Singh Anand Rotte Anthony A. Golsorkhi Sandhya Girish

Introduction Bladder cancer (BC) is the sixth most common type of cancer with epithelial/urothelial and non-urothelial origins. Urothelial carcinoma (UC) involves neoplastic cells of epithelial origin and accounts for 90% of all BC cases. Current review aims to discuss the latest advances and challenges in the treatment of UC with an emphasis on clinical pharmacology considerations.Areas covered Data including clinical efficacy and safety outcomes as well as precautions reported in published clinical studies obtained from PubMed and package inserts were collected and summarized in the review. Recent decade saw the approval of multiple drugs for the treatment of BC in both adjuvant/neoadjuvant setting as well as for unresectable tumors. Checkpoint blockers (pembrolizumab, nivolumab, atezolizumab, and avelumab), antibody drug conjugates (enfortumab vedotin and sacituzumab govitecan) and targeted therapies (erdafitinib) are now available in first-line (cisplatin-ineligible), second-line and third-line settings along with conventional platinum-based chemotherapy. While the survival outcomes have improved especially in refractory and unresponsive patients, the response rates are relatively low and patient safety needs further optimization.Expert opinion Additional studies on combination therapies, dose adjustments in special populations and impact of anti-drug antibodies on drug exposure are needed to further improve clinical outcomes.

Atezolizumab

Avelumab

Metastatic Urothelial Carcinoma

10.1080/17512433.2023.2219446

Cite

Citations (3)

Blockade of programmed cell death protein-1 pathway for the treatment of melanoma

Deleted Journal (2017)

Madhuri Bhandaru Anand Rotte

Abstract Metastatic melanoma is a very deadly type of skin cancer with poor prognosis and low 5-year survival rates. Until recently, patients with metastatic melanoma had very few treatment options, which only included dacarbazine and aldesleukin. In 2011, the first checkpoint blocker, ipilimumab was approved for the treatment of unresectable metastatic melanoma but its success was eclipsed by low response rates and high incidence of adverse events. Later in 2014, anti-PD-1 antibodies, nivolumab and pembrolizumab were approved for the treatment of metastatic melanoma. With comparatively high response rates and manageable safety profile, PD-1 blockers were remarkably successful in the treatment of melanoma and also other cancer subtypes such as non-small cell lung cancer and metastatic urothelial carcinoma. This article highlights the success of anti-PD-1 antibodies, discusses the mechanism of PD-1:PD-L1/2 pathway, responses of melanoma patients to PD-1 blockers and the research on improving response rates to PD-1 blockers.

Dacarbazine

Immune checkpoint

10.14302/issn.2471-2175.jdrt-17-1760

Cite

Citations (17)